H.C. Wainwright Keeps Their Buy Rating on Phasebio Pharmaceuticals (PHAS)
TipRanksAug 15, 2022 06:20 ET
PhaseBio Pharmaceuticals Price Target Cut to $8.00/Share From $10.00 by Needham
Dow JonesAug 15, 2022 04:42 ET
PhaseBio Pharmaceuticals Is Maintained at Buy by Needham
Dow JonesAug 15, 2022 04:42 ET
Needham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $8
Benzinga Real-time NewsAug 15, 2022 04:34 ET
Phasebio Pharmaceuticals (PHAS) Receives a Buy from Needham
TipRanksAug 12, 2022 16:25 ET
Analysts Offer Insights on Healthcare Companies: Knight Therapeutics (OtherKHTRF) and Phasebio Pharmaceuticals (PHAS)
TipRanksAug 12, 2022 16:25 ET
No Data
No Data